DAM for pharma and life sciences: fit criteria and candidate vendors

Asset types in pharma and life sciences

A pharma and life sciences DAM holds promotional, scientific, patient and packaging content, and each item carries a review status, a market and an expiry date. The library differs from a consumer brand library because every promotional asset is tied to a regulatory approval in one or more markets.

Typical asset families:

• Healthcare professional (HCP) materials: detail aids, leave pieces, approved emails, congress booths and posters.
• Patient and public materials: disease awareness content, patient support programme assets and leaflets.
• Scientific content: mode of action animations, expert videos and the reference documents that support each claim.
• Product and packaging: pack shots, packaging artwork and labelling components, often managed with a packaging workflow.
• Corporate and brand assets: logos, photography, templates and investor materials.

The metadata model decides whether the DAM can control this content. DAMSelection assessment: design the metadata schema before the first demo. The minimum field set covers product, indication, market, language and audience (HCP, patient or public). Add supply classification, review job code, approval date, date of first dissemination and expiry or re-certification date. Close with linked claim IDs and the summary of product characteristics (SmPC) version the asset complies with.

Regulation that shapes the DAM

Pharma DAM requirements trace back to advertising law for medicinal products and, for US-regulated records, to electronic record rules. The DAM rarely appears in the law by name. The law sets duties that the DAM must make provable.

European Union

Fact: Titles VIII and VIIIa of Directive 2001/83/EC (Articles 86 to 100) govern advertising of medicinal products for human use. The provisions that turn into DAM requirements:

Fact: on 14 October 2026 the reform that repeals Directive 2001/83/EC, procedure 2023/0132(COD), awaits the European Parliament's second reading. The Council position was published on 1 October 2026. Buyers should check the Legislative Observatory for the final act and its application date before contract signature. National codes of practice add further rules per market.

United States

Fact: 21 CFR 314.81(b)(3)(i) requires the applicant to submit specimens of promotional labeling and advertising at the time of initial dissemination or publication, with a completed Form FDA-2253. A DAM that records first-use dates per asset supports this duty.

Fact: 21 CFR Part 11 applies to electronic records kept under FDA record requirements and to records submitted to FDA. Section 11.10(e) requires secure, computer-generated, time-stamped audit trails, and record changes must not obscure previously recorded information. Section 11.50 requires signed records to show the signer's printed name, the date and time and the meaning of the signature. FDA guidance from 2003 states that predicate rules decide which records fall under Part 11, so the quality team decides whether the DAM holds Part 11 records.

Where MLR review lives

The first architecture decision in a pharma DAM selection is which system holds the MLR approval record. Three patterns occur in practice:

1. The DAM runs MLR review: one system, but the DAM's workflow, audit trail and electronic signatures then need validation.
2. A dedicated promotional review system holds the approval, and the DAM stores and distributes approved finals with the job code as the link.
3. Hybrid: review happens in the review system and the DAM manages work-in-progress creative, final storage, expiry and distribution.

DAMSelection assessment: pattern 2 is the most common in companies that already run a promotional review system. The DAM then needs a dependable integration, expiry enforcement and an audit trail of distribution, and it carries less validation burden. Pattern 1 suits smaller life sciences companies without a review system, provided the vendor can supply validation documentation.

Fit criteria and weights

Pharma and life sciences buyers should weight workflow, compliance evidence and metadata control highest. The table uses the twelve DAMSelection scoring criteria; adjust the weights to the review pattern you chose.

Score each candidate with the public scoring matrix. The financial services and consumer packaged goods fit pages cover comparable approval and artwork patterns, and DAM by industry lists all ten industries. The candidate table on this page lists platforms from the enterprise content platforms and European specialists segments; the regulated industries shortlist adds scored scenarios.

Scenarios to script

Pharma demos should test expiry, approval evidence and market control on your own assets. DAMSelection assessment: generic vendor demos carry no selection value here, because every vendor shows a review workflow. Generate the scripts with the Demo Script Generator.

Scenario 1: SmPC update and expiry cascade

Load 60 assets for one product across Germany, the Netherlands and France, linked to SmPC version 4. Announce that version 5 replaces it. Ask the vendor to find every affected asset within three filters, expire them at a set date, notify asset owners and show that expired assets stop resolving on portal and delivery URLs. Ask for the audit trail export afterwards.

Scenario 2: Approved final arrives from the review system

Push an approved detail aid with job code, approval date and expiry date from the review system through the API. Ask the vendor to lock the file, publish it to the German HCP portal only, record the date of first dissemination and show the signature manifestation fields if the DAM holds the approval.

Scenario 3: Affiliate adaptation

An affiliate in France adapts the core asset with a local claim. Ask the vendor to show the derivative linked to its parent, the trigger for local re-review and the stored sample record with audience, channel and first-use date.

Integrations

A pharma DAM sits between the promotional review system, the commercial channels and the regulatory record of product information. Check each integration in the demo with real job codes.

For consumer health ranges sold through retail, check PIM integration depth as well.

Pitfalls

Pharma DAM projects fail most often on expiry enforcement and on unclear ownership of the approval record. Five pitfalls recur in DAMSelection practice:

• Expired assets stay live on CDN links, embedded web pages and rep devices after the DAM status changes.
• The team treats a DAM approval step as MLR approval without validating it.
• HCP and public content share one portal with one permission set, which breaks the Article 88 separation.
• Job codes are typed by hand, so the link between the DAM and the review system breaks.
• Validation effort per vendor release is missing from the total cost of ownership model.